FDA approves pancreatic cancer drug that nearly doubles survival

The FDA approved Rasonque (daraxonrasib), a targeted therapy for advanced pancreatic cancer, which nearly doubles median overall survival to 13.2 months compared to 6.7 months with standard chemotherapy. This is the first approved drug targeting multiple forms of the RAS protein, addressing a long-standing treatment gap in pancreatic adenocarcinoma.

This Wire brief sits within Fusion42's coverage of Biotech, and 20 sources have reported it.